{rfName}
Ma

Indexed in

License and use

Citations

185

Altmetrics

Analysis of institutional authors

Arribas, Jose RAuthor

Share

November 16, 2022
Publications
>
Article
No

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

Publicated to:HIV MEDICINE. 23 (8): 849-858 - 2022-03-25 23(8), DOI: 10.1111/hiv.13268

Authors: Ryom, Lene; De Miguel, Rosa; Cotter, Aoife Grace; Podlekareva, Daria; Beguelin, Charles; Waalewijn, Hylke; Arribas, Jose R.; Mallon, Patrick W. G.; Marzolini, Catia; Kirk, Ole; Bamford, Alasdair; Rauch, Andri; Molina, Jean Michel; Kowalska, Justyna Dominika; Guaraldi, Giovanni; Winston, Alan; Boesecke, Christoph; Cinque, Paola; Welch, Steven; Collins, Simon; Behrens, Georg M. N.;EACS Governing Board

Affiliations

Bern Univ Hosp, Dept Infect Dis, Inselspital, Bern, Switzerland - Author
Bispebjerg Hosp, Dept Resp Med, Copenhagen, Denmark - Author
Bonn Univ Hosp, Dept Med 1, Bonn, Germany - Author
EATG, London, England - Author
German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, Hannover, Germany - Author
Great Ormond St Hosp Children NHS Fdn Trust, London, England - Author
Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany - Author
HIV I Base, London, England - Author
Hvidovre Univ Hosp, Dept Infect Dis 144, Copenhagen, Denmark - Author
Imperial Coll London, Dept Infect Dis, Sect Virol, London, England - Author
Ist Sci San Raffaele, Unit Infect Dis, Milan, Italy - Author
Mater Misericordiae Univ Hosp Dublin, Dublin, Ireland - Author
Med Univ Warsaw, Fac Med, Warsaw, Poland - Author
Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci RIHS, Dept Pharm, Nijmegen, Netherlands - Author
Univ Basel, Basel, Switzerland - Author
Univ Coll Dublin, Ctr Expt Pathogen Host Res, Dublin, Ireland - Author
Univ Copenhagen, Rigshosp, Ctr Excellence & Lealth Immun & Infect, CHIP, Sect 2100, DK-2100 Copenhagen O, Denmark - Author
Univ Copenhagen, Rigshosp, Dept Infect Dis, Copenhagen, Denmark - Author
Univ Hosp Basel, Dept Clin Res, Basel, Switzerland - Author
Univ Hosp Basel, Dept Med, Basel, Switzerland - Author
Univ Hosp Birmingham NHS Fdn Trust, Dept Paediat, Birmingham, W Midlands, England - Author
Univ Hosp La Paz, HIV Infect Dis Unit, Internal Med, Madrid, Spain - Author
Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England - Author
Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Modena, Italy - Author
Univ Paris, St Louis & Lariboisiere Hosp, AP HP, Dept Infect Dis, Paris, France - Author
See more

Abstract

Background The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV care. Key points of the Guidelines update Version 11.0 of the Guidelines recommend six first-line treatment options for antiretroviral treatment (ART)-naive adults: tenofovir-based backbone plus an unboosted integrase inhibitor or plus doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. Recommendations on preferred and alternative first-line combinations from birth to adolescence were included in the new paediatric section made with Penta. Long-acting cabotegravir plus rilpivirine was included as a switch option and, along with fostemsavir, was added to all drug-drug interaction (DDI) tables. Four new DDI tables for anti-tuberculosis drugs, anxiolytics, hormone replacement therapy and COVID-19 therapies were introduced, as well as guidance on screening and management of anxiety disorders, transgender health, sexual health for women and menopause. The sections on frailty, obesity and cancer were expanded, and recommendations for the management of people with diabetes and cardiovascular disease risk were revised extensively. Treatment of recently acquired hepatitis C is recommended with ongoing risk behaviour to reduce transmission. Bulevirtide was included as a treatment option for the hepatitis Delta virus. Drug-resistant tuberculosis guidance was adjusted in accordance with the 2020 World Health Organization recommendations. Finally, there is new guidance on COVID-19 management with a focus on continuance of HIV care. Conclusions In 2021, the EACS Guidelines were updated extensively and broadened to include new sections. The recommendations are available as a free app, in interactive web format and as an online pdf.

Keywords

antiretroviral treatmentchildrencomorbiditiescovid-19drug-drug interactionseuropean aids clinical society (eacs) guidelineshepatitis b virushepatitis c virushivpentaAntiretroviral treatmentChildrenComorbiditiesCovid-19Drug-drug interactionsEuropean aids clinical society (eacs) guidelinesHepatitis b virusHepatitis c virusHivOpportunistic infectionsPentaRegimens

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal HIV MEDICINE due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Health Policy.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 9.5. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 42.51 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-08, the following number of citations:

  • WoS: 42
  • Google Scholar: 65

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-08:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 200.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 206 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 17.75.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).
  • The number of mentions in news outlets: 2 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Denmark; France; Germany; Italy; Netherlands; Poland; Switzerland; United Kingdom.